Clinical trials: Residual Disease
Acute Myeloid Leukemia
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
This is a non-randomized, open-label, multicenter, dose escalation study designed to determine the maximum tolerated dose (MTD) of SL-401 in adult patients with acute myeloid leukemia, and to evaluate the safety profile of SL-401…
- Trial name
- NCT02270463
- Testing
- Tagraxofusp-erzs
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia
In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in individual patients must be individualized. One of the tools for this is molecular-cytogenetic stratification.
- Trial name
- PALG-AML2012 (NCT02072811)
- Testing
- DAC, CLAG, Consolidation, I HAM cycle
- Where
- Poland
- Volunteers
- 400 people
- Sponsor
- dr hab. n. med. Agnieszka Wierzbowska
Triple-Negative Invasive Breast Carcinoma, Residual Tumor
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. Its incidence is approximately 180,000 cases per year.
- Trial name
- NCT02670109
- Testing
- Carmustine, Cyclophosphamide, Carboplatin
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Cementation (MeSH Unique ID: D002484), Dental Implant-Abutment Design (MeSH Unique ID: D059605)
Cementation Techniques for Single-tooth Implant Crowns
Cement retention has been widely used for implant-supported fixed partial dentures in daily dental practice. The cementation approach indeed offers straightforward clinical application protocol which is basically conceptualized…
- Conditions
- Cementation (MeSH Unique ID: D002484), Dental Implant-Abutment Design (MeSH Unique ID: D059605), Crown (MeSH Unique ID: D003442) Surfaces, Contour: Crown (MeSH Unique ID: D003442) - Dental Implant (MeSH Unique ID: D015921) Abutment
- Trial name
- NCT03581565
- Testing
- zinc polycarboxylate (with the requirements of ISO 9917)
- Where
- Turkey (Türkiye)
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Kıvanç Akça
Lung Neoplasms, Pancreatic Neoplasms
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
This is a combined prospective and retrospective observational study aiming to validate a highly sensitive and specific blood-based method for the early diagnosis and post-treatment monitoring of multiple cancers.
- Conditions
- Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms
- Trial name
- NCT07035587
- Testing
- Serial Blood Sampling for Molecular Profiling, One-Time Blood Sampling for Molecular Profiling
- Where
- South Korea
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Malaria
RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission
Reactive treatment of household contacts of a confirmed malaria case has been shown to reduce infection prevalence since the former as they are at an increased risk of infection.
- Trial name
- RHOST (NCT02878200)
- Testing
- dihydroartemisinin-piperaquine
- Where
- The Gambia
- Volunteers
- 2,236 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Anemia
Placental Transfusion in Term Infants: A Pilot Study
The proposed study is a pilot prospective controlled trial to measure the blood volume left in the placenta after varying cord clamping times when the infant is placed skin-to-skin on the maternal abdomen.
- Trial name
- NCT01924572
- Testing
- cord clamping at 2 minutes, cord clamping at 5 minutes, cord milking
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Rhode Island
Periodontitis
Granulation Tissue From Residual Periodontal Pockets
This observational study aims to describe the histopathological features of granulation tissue (GT) found in residual periodontal pockets at the time of surgical intervention, after completion of the first two steps of…
- Trial name
- GTRP (NCT07587606)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- University of Roma La Sapienza
Lung Non-Small Cell Carcinoma
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients…
- Trial name
- NCT07293247
- Testing
- Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy
- Where
- 125 sites in United States
- Volunteers
- 164 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Triple Negative Breast Cancer
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NECTAR (NCT01931163)
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jenny C. Chang, MD
Primary Breast Cancer
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases.
- Trial name
- MRD-1 (NCT00172068)
- Testing
- Zoledronic acid + Calcium/Vitamin D
- Where
- 4 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Intracerebral Hemorrhage, Brain Hematoma
Microplastics in Brain Hematomas and Neurological Outcomes After Intracerebral Hemorrhage
This observational study investigates the presence of micro- and nanoplastics in surgically removed intracerebral hematomas and their association with neurological outcomes in patients with spontaneous intracerebral hemorrhage.
- Trial name
- PARTENOPE (NCT07580326)
- Testing
- Observational Analysis
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Campania Luigi Vanvitelli
Hepatic Cystic Echinococcosis
Omentoplasty Versus Tube Drainage for Residual Cavity Management in Complicated Hepatic Cystic Echinococcosis
This prospective comparative study evaluated two surgical techniques for residual cavity management following conservative surgery for complicated hepatic cystic echinococcosis.
- Trial name
- NCT07793448
- Testing
- omentoplasty, External Tube Drainage
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Ataturk University
Hemodialysis, Kidney Failure, Chronic
Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.
- Trial name
- NCT03874117
- Testing
- Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis, Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Palo Alto Veterans Institute for Research
Relapsed/Refractory AML, Minimal Residual Disease Positive AML
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have myeloid malignancies, and to determine the maximum tolerated dose…
- Conditions
- Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome
- Trial name
- NCT02520427
- Testing
- AMG 330
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Amgen
Locally Advanced Head and Neck Carcinoma
Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer
Sixty percent of newly diagnosed head and neck squamous cell carcinomas (HNSCCs) are at a locally advanced (LA) stage. Depending on tumor site, stage, and resectability, locoregional failure rates can range from 35% to 65%.
- Trial name
- NeckTAR (NCT05710679)
- Testing
- Blood sample
- Where
- 4 sites in France
- Volunteers
- 63 people
- Sponsor
- Centre Jean Perrin
Nasopharyngeal Neoplasms
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
This study will enroll patients with non-metastatic nasopharyngeal carcinoma (NPC) that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy.
- Trial name
- ADVANCE (NCT02874651)
- Testing
- Apatinib
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Galactose Single Point (GSP), Residual Liver Function
GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver
The primary objective is to determine the galactose single point (GSP) cutoff values to discriminate subjects with different hepatic function.
- Trial name
- GSP (NCT04546022)
- Testing
- Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- National Defense Medical Center, Taiwan
Peripheral Arterial Disease
BIO REsponse Adapted Combination Therapy Pilot Study
Both drug-coated balloon and stents have been used for a number of years to treat subjects with Peripheral Artery Disease (PAD) and are recognized as very good treatment methods.
- Trial name
- NCT03547986
- Testing
- Duplex Ultrasound (DUS), IVUS with Intraarterial pressure measurement (IAP) if needed
- Where
- 15 sites in Australia, Austria and 4 more
- Volunteers
- 150 people
- Sponsor
- Biotronik AG
Acute Myeloid Leukemia, Minimal Residual Disease Negativity
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
This phase II trial studies how well autologous stem cell transplant works in treating patients with favorable or intermediate risk, minimal residual disease (MRD)-negative, acute myeloid leukemia.
- Trial name
- NCT03515707
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Etoposide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.